Evidence map›Paper›PMID 34474640›Full record

ArticleLeukemia & lymphoma2021

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.

Sangeetha Venugopal, Abhishek Maiti, Courtney D DiNardo, Wei Qiao, Jing Ning, Sanam Loghavi, Naval G Daver, Tapan M Kadia, Caitlin R Rausch, Yesid Alvarado and 8 more

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Sangeetha VenugopalDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abhishek MaitiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei QiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jing NingDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naval G DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tapan M KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Caitlin R RauschDepartment of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yesid AlvaradoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maro OhanianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Musa YilmazDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marina Y KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting mitochondrial complex I in acute lymphoblastic leukemiaR01CA231364 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2019 to 2024
$2.9M
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimenR01CA235622 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y, SPENCER, DAVID H · 2019 to 2024
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA231364NCI NIH HHS R01 CA235622
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsAzacitidineCytogenetic AnalysisDecitabineHumansPrognosisSulfonamidesAzacitidineBridged Bicyclo Compounds, HeterocyclicDecitabineSulfonamidesvenetoclax

Identifiers

PMID34474640
PMCPMC10423012
OpenAlexW3197239603

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.